BTIG analyst Mark Massaro reiterated a Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report) yesterday and set a price target of $2.50. The company’s shares closed yesterday at $2.22.
According to TipRanks, Massaro is an analyst with an average return of -10.5% and a 34.82% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Renalytix AI, and Exact Sciences.
Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Hold with an average price target of $2.65, a 19.37% upside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $3.00 price target.
See the top stocks recommended by analysts >>
DNA market cap is currently $4.61B and has a P/E ratio of -3.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
Read More on DNA:
- Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet Partnership
- Ginkgo Bioworks, ILRI enter MoU to collaborate on pandemic surveillance work
- Ginkgo Bioworks files to sell 5.28M shares of Class A common stock for holders
- Cathie Wood Pursues Innovation in Smaller Stocks
- Cathie Wood’s ARK Investment bought 203K shares of Ginkgo Bioworks today
